Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-02-20
2008-09-09
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007920, C436S518000, C436S164000
Reexamination Certificate
active
07422864
ABSTRACT:
The present invention provides a method for measuring a “complex of oxidized LDL and CRP” which comprises using an “anti-CRP antibody”. An “anti-apoB antibody and/or anti-β2-GPI antibody” is preferably used in the method of the present invention, which preferably comprises at least a step for forming a sandwich complex represented by “the anti-apoB antibody and/or anti-β2-GPI antibody”-“the complex of oxidized LDL and CRP”-“the anti-CRP antibody”. Either the “anti-apoB antibody and/or anti-β2-GPI antibody” or the “anti-CRP antibody” is preferably immobilized on a solid phase. According to the measuring method of the present invention, the “complex of oxidized LDL and CRP” may be simply, promptly and easily measured with high sensitivity, high accuracy at a lower cost.
REFERENCES:
patent: 4933275 (1990-06-01), Wands et al.
patent: 5272258 (1993-12-01), Siegel et al.
patent: 5500345 (1996-03-01), Soe et al.
patent: 5900359 (1999-05-01), Matsuura et al.
patent: 6432632 (2002-08-01), Nakayama et al.
patent: 2002/0150890 (2002-10-01), Nakayama et al.
patent: 2002/0193949 (2002-12-01), Fischer et al.
patent: 2003/0077668 (2003-04-01), Uchida et al.
patent: 2005/0181451 (2005-08-01), Bates
patent: 1 070 962 (2001-01-01), None
patent: 2001-324506 (2001-11-01), None
patent: 95/09363 (1995-04-01), None
patent: 95-09363 (1995-04-01), None
K. Kobayashi et al., “A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages”, Journal of Lipid Research, vol. 42, pp. 697-709, 2001.
J. Hulthe et al., “Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the Atherosclerosis and Insulin resistance (AIR) study”, Clinical Science, vol. 100, pp. 371-378, 2001.
M. Ryan et al., “Antibodies to oxidized lipoproteins and their relationship to myocardial infarction”, QJ Med., vol. 91, pp. 411-415, 1998.
M. Chang et al., “C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized pohspholipids”, PNAS, vol. 99, No. 20, pp. 13043-13048, Oct. 1, 2002.
C. Monaco et al., “Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease”, European Heart Journal, vol. 22, pp. 1572-1577, 2001.
Y. Hasunuma et al., “Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages”, Clin. Exp. Immunol., vol. 107, pp. 569-573, 1997.
J. George et al., “Induction of Early Atherosclerosis in LDL-Receptor-Deficient Mice Immunized with β2-Glycoprotein I”, Circulation, vol. 98, pp. 1108-1115, 1998.
P. Holvoet et al., “Oxidized LDL and Malondialdehyde-Modified LDL in Patients with Acute Coronary Syndromes and Stable Coronary Artery Disease”, Circulation, vol. 98, pp. 1487-1494, 1998.
J. George et al., “Immunolocalization of β2-Glycoprotein I (Apolipoprotein H) to Human Atherosclerotic Plaques”, Circulation, vol. 99, pp. 2227-2230, 1998.
Q. Liu et al., “ω-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages”, Journal of Lipid Research, vol. 43, No. 9, pp. 1486-1495, 2002.
E. Matsuura et al., “Anti-β2-Glycoprotein I Autoantibodies and Atherosclerosis”, Intern. Rev. Immunol., vol. 21, pp. 51-56, Jan. and Feb. 2002.
J. George et al., Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS), Clin. Exp. Immunol., vol. 108, pp. 227-233, May 1997.
Chang et al., “C-Reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids”, Proc. Natl. Acad. Sci., vol. 99, pp. 13043-13048, 2002.
Mi-Kyung Chang et al., “C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids”, Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, vol. 99, No. 20, pp. 13043-13048 (2002).
Kazuko Kobayashi et al., “Circulation oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen”, Journal of Lipid Research, vol. 44, pp. 716-726 (2003).
Eiji Matsuura et al., “Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis”, Progress in Lipid Research, vol. 45, No. 6, pp. 466-486 (2006).
Masako Tabuchi et al., “The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis”, Journal of Lipid Research, vol. 48, pp. 768-781 (2007).
Counts Gary W
Le Long V.
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Method for measuring oxidized LDL-CRP complex and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for measuring oxidized LDL-CRP complex and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for measuring oxidized LDL-CRP complex and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986596